2022
Cancer of the Lung
Morgensztern D, Boffa D, Chen A, Dhanasopon A, Goldberg S, Decker R, Devarakonda S, Ko J, Soto L, Waqar S, Wistuba I, Herbst R. Cancer of the Lung. 2022, 1-29. DOI: 10.1002/9781119000822.hfcm085.pub2.Peer-Reviewed Original Research
2020
Comprehensive T cell repertoire characterization of non-small cell lung cancer
Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications 2020, 11: 603. PMID: 32001676, PMCID: PMC6992630, DOI: 10.1038/s41467-019-14273-0.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerT cellsLung cancerAdoptive T-cell therapyEarly-stage NSCLC patientsT cell repertoire analysisT cell responsesLungs of patientsT-cell therapyNSCLC patientsInferior survivalClinicopathologic featuresImmune landscapeViral infectionSolid tumorsTherapeutic efficacyCell responsesCell therapyPatientsRepertoire analysisLungTumorsImmunotherapyConsiderable proportion
2019
MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer
Reuben A, Zhang J, Gittelman R, Chiou S, Li J, Fujimoto J, Behrens C, Kheradmand F, Chow C, Bernatchez C, Eterovic A, Benzeno S, Vignali M, Wu X, Ye Y, Cascone T, Herbst R, Swisher S, Kadara H, Moran C, Zhang J, Scheet P, Vaporciyan A, Sepesi B, Gibbons D, Robins H, Hwu P, Heymach J, Sharma P, Allison J, Lee J, Davis M, Wistuba I, Futreal P, Zhang J. MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2019, 14: s293. DOI: 10.1016/j.jtho.2019.08.589.Peer-Reviewed Original Research
2017
Cancer of the Lung
Lu C, Morgensztern D, Chiang A, Onn A, Sepesi B, Vaporciyan A, Chang J, Komaki R, Wistuba I, Herbst R. Cancer of the Lung. 2017, 1-30. DOI: 10.1002/9781119000822.hfcm085.Peer-Reviewed Original ResearchLung cancerLung cancer mortalityStandard therapy optionsCancer-related deathNovel therapeutic strategiesCancer mortalityTherapy optionsHeterogeneous diseaseTherapeutic strategiesTobacco consumptionCancerMolecular pathwaysCurrent standardImmunotherapyChemotherapySurgeryRadiotherapyLungTherapyMortalityDiseaseSignificant excitementCare
2015
Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clinical Cancer Research 2015, 21: 1514-1524. PMID: 25680375, PMCID: PMC4654466, DOI: 10.1158/1078-0432.ccr-13-3473.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaLung squamous cell carcinomaMaster protocolsClinical trialsAdvanced lung squamous cell carcinomaSquamous cell lung cancerCell lung cancerStandard of careMutation/amplificationTraditional clinical trialsDevelopment of therapiesInvestigational agentsCell carcinomaLung cancerCancer Genome Atlas (TCGA) projectMolecular abnormalitiesTherapyLungTrialsSignificant numberCarcinomaCancerAbnormalitiesProtocolCare
2014
“Quitting Smoking Will Benefit Your Health”: The Evolution of Clinician Messaging to Encourage Tobacco Cessation
Toll BA, Rojewski AM, Duncan LR, Latimer-Cheung AE, Fucito LM, Boyer JL, O'Malley SS, Salovey P, Herbst RS. “Quitting Smoking Will Benefit Your Health”: The Evolution of Clinician Messaging to Encourage Tobacco Cessation. Clinical Cancer Research 2014, 20: 301-309. PMID: 24436474, PMCID: PMC3927319, DOI: 10.1158/1078-0432.ccr-13-2261.Peer-Reviewed Original ResearchConceptsCancer-related deathHeart diseaseTobacco useLung cancer-related deathsSubgroups of smokersBurden of cancerModerators of treatmentAdult patientsCessation interventionsSmoking cessationTobacco cessationQuitting smokingPreventable deathsGain-framed messagesSmokingTobacco productsCancerDiseaseDeathPatientsLungStrokeCessationHealthFuture studies
2012
Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
Subbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock R. Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist. Molecular Cancer Therapeutics 2012, 11: 2541-2546. PMID: 22914439, PMCID: PMC3496030, DOI: 10.1158/1535-7163.mct-12-0358.Peer-Reviewed Original ResearchMeSH KeywordsApoptosisBone NeoplasmsCell SurvivalChondrosarcomaDNA Mutational AnalysisHumansImmunohistochemistryIsocitrate DehydrogenaseLung NeoplasmsMaleMiddle AgedProteomicsProto-Oncogene Proteins c-bcl-2Radiography, ThoracicReceptors, Death DomainRecombinant ProteinsSignal TransductionTNF-Related Apoptosis-Inducing LigandTomography, X-Ray ComputedTreatment OutcomeConceptsRecombinant human Apo2L/TRAILApo2L/TRAILRecent computed tomography scanSustained partial responseEvidence of diseaseComputed tomography scanP-ERK 1/2Partial responseProgressive diseaseNF-κBp65Receptor agonistTomography scanSubcentimeter nodulesPatient tumorsMetastatic chondrosarcomaP-mTORPatientsProlonged responseP-STAT3Proapoptotic receptor agonistsChondrosarcomaBcl-2DulanerminLungTumors
2005
P-762 Limited small cell lung cancer (LSCLC) — observations from the National Cancer Database on the impact of age, gender and treatment on survival
Gaspar L, Gay G, Crawford J, Putnam J, Herbst R, Bonner J. P-762 Limited small cell lung cancer (LSCLC) — observations from the National Cancer Database on the impact of age, gender and treatment on survival. Lung Cancer 2005, 49: s319. DOI: 10.1016/s0169-5002(05)81255-3.Peer-Reviewed Original Research
2004
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC)
Tran H, Zinner R, Blumenschein G, Oh Y, Papadimitrakopoulou V, Kim E, Lu C, Malik M, Lum B, Herbst R. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC). Journal Of Clinical Oncology 2004, 22: 2050-2050. DOI: 10.1200/jco.2004.22.14_suppl.2050.Peer-Reviewed Original ResearchPharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC)
Tran H, Zinner R, Blumenschein G, Oh Y, Papadimitrakopoulou V, Kim E, Lu C, Malik M, Lum B, Herbst R. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC). Journal Of Clinical Oncology 2004, 22: 2050-2050. DOI: 10.1200/jco.2004.22.90140.2050.Peer-Reviewed Original Research